文献速递免疫规划传染病防控与疫情报告

2023-2024年更新版(单价XBB.1.5)COVID-19疫苗对免疫正常成人有症状SARS-CoV-2感染(归因于共循环奥密克戎变异株)的早期有效性估计——增加社区检测可及性项目,美国,2023年9月至2024年1月

Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2024-02-01

利用增加社区检测可及性药房检测项目数据,估计2023-2024年更新版COVID-19疫苗对≥18岁免疫正常成人有症状SARS-CoV-2感染的有效性。在9,222份合格检测中,总体疫苗有效性为54%(95%CI=46%-60%),接种后中位52天。在2,199份具备S基因靶标失败(SGTF)检测的样本中,接种后60-119天,SGTF阳性样本疫苗有效性为49%(95%CI=19%-68%),SGTF阴性样本为60%(95%CI=35%-75%)。

要点

  • 更新版COVID-19疫苗对成人有症状SARS-CoV-2感染的总体有效性为54%(95%CI=46%-60%)。
  • 接种后60-119天,SGTF阳性(提示JN.1)样本疫苗有效性49%(95%CI=19%-68%),SGTF阴性样本60%(95%CI=35%-75%)。
  • 所有≥6月龄人群应接种更新版COVID-19疫苗。

核心结论

  • 更新版COVID-19疫苗对有症状感染提供保护,包括对当前流行谱系。
  • CDC将继续监测疫苗有效性,包括预期减弱和对重症的保护。

研究设计与样本

  • 分析增加社区检测可及性SARS-CoV-2药房检测项目数据,估计更新版COVID-19疫苗有效性(接种对比未接种)对有症状SARS-CoV-2感染,包括按SGTF结果分层。
  • 共纳入9,222份合格检测,对象为≥18岁免疫正常成人。

主要发现

  • 总体疫苗有效性为54%(95%CI=46%-60%),接种后中位52天。
  • 在2,199份具备SGTF检测的样本中,接种后60-119天,SGTF阳性样本疫苗有效性为49%(95%CI=19%-68%)。
  • 在2,199份具备SGTF检测的样本中,接种后60-119天,SGTF阴性样本疫苗有效性为60%(95%CI=35%-75%)。

关键数值与推荐

  • CDC免疫实践咨询委员会于2023年9月12日推荐所有≥6月龄人群接种更新版2023-2024(单价XBB.1.5衍生)COVID-19疫苗以预防COVID-19包括重症。
  • 所有≥6月龄人群应接种更新版COVID-19疫苗剂量。

临床怎么用

  • 所有≥6月龄人群应接种更新版COVID-19疫苗剂量。
  • CDC将继续监测疫苗有效性,包括预期减弱和对重症的保护。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

On September 12, 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (updated) COVID-19 vaccination with a monovalent XBB.1.5-derived vaccine for all persons aged ≥6 months to prevent COVID-19, including severe disease. During fall 2023, XBB lineages co-circulated with JN.1, an Omicron BA.2.86 lineage that emerged in September 2023. These variants have amino acid substitutions that might increase escape from neutralizing antibodies. XBB lineages predominated through December 2023, when JN.1 became predominant in the United States. Reduction or failure of spike gene (S-gene) amplification (i.e., S-gene target failure [SGTF]) in real-time reverse transcription-polymerase chain reaction testing is a time-dependent, proxy indicator of JN.1 infection. Data from the Increasing Community Access to Testing SARS-CoV-2 pharmacy testing program were analyzed to estimate updated COVID-19 vaccine effectiveness (VE) (i.e., receipt versus no receipt of updated vaccination) against symptomatic SARS-CoV-2 infection, including by SGTF result. Among 9,222 total eligible tests, overall VE among adults aged ≥18 years was 54% (95% CI = 46%-60%) at a median of 52 days after vaccination. Among 2,199 tests performed at a laboratory with SGTF testing, VE 60-119 days after vaccination was 49% (95% CI = 19%-68%) among tests exhibiting SGTF and 60% (95% CI = 35%-75%) among tests without SGTF. Updated COVID-19 vaccines provide protection against symptomatic infection, including against currently circulating lineages. CDC will continue monitoring VE, including for expected waning and against severe disease. All persons aged ≥6 months should receive an updated COVID-19 vaccine dose.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Link-Gelles R, Ciesla AA, Mak J, et al. Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38300853. doi:10.15585/mmwr.mm7304a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。